Table 2.

Cell-surface reactivity of post-alloHSCT serum antibodies

	Autologous B-CLL cells	Autologous T cells	Allogeneic B cells	Third-party B cells
Patient A after 6 m plasma	++*	+	−†	Weak
Patient B after 10 m plasma	++	Weak	++‡	+
Rituximab	++ (Patient A)	− (Patient A)	++	++
	+ (Patient B)	− (Patient B)	++	++
Alemtuzumab	+++ (Patient A)	− (Patient A)	+++	+++
	+++ (Patient B)	− (Patient B)	+++	+++

− indicates < 2; weak, ≥ 2 and < 5; +, ≥ 5 and < 20; ++, ≥ 20 and < 100; and +++, ≥ 100

^*Based on median fluorescence intensity (MFI) ratios calculated for sample over background.

^†Allogeneic B cells derived from PBMCs of patient A 15 months after transplantation.

^‡Allogeneic B cells derived from PBMCs of the donor of patient B.